{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:10:21Z","timestamp":1785435021402,"version":"3.56.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"am","delay-in-days":293,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI101047"],"award-info":[{"award-number":["R01AI101047"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI143844"],"award-info":[{"award-number":["R01AI143844"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.nano.2022.102614","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T13:59:29Z","timestamp":1666015169000},"page":"102614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Monophosphoryl lipid A-adjuvanted nucleoprotein-neuraminidase nanoparticles improve immune protection against divergent influenza viruses"],"prefix":"10.1016","volume":"47","author":[{"given":"Ye","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wandi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvinder Singh","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy L.","family":"Denning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Moo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2022.102614_bb0005","unstructured":"Centers for Disease Control and Prevention, Past Seasons Vaccine Effectiveness Estimates, https:\/\/www.cdc.gov\/flu\/vaccines-work\/past-seasons-estimates.html, accessed: September 27, 2022."},{"key":"10.1016\/j.nano.2022.102614_bb0010","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/infdis\/jiy103","article-title":"A universal influenza vaccine: the strategic plan for the national institute of allergy and infectious diseases","volume":"218","author":"Erbelding","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.nano.2022.102614_bb0015","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.nano.2022.102614_bb0020","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41467-017-02725-4","article-title":"Double-layered protein nanoparticles induce broad protection against divergent influenza a viruses","volume":"9","author":"Deng","year":"2018","journal-title":"Nat.Commun."},{"key":"10.1016\/j.nano.2022.102614_bb0025","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/mt.2012.246","article-title":"Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus","volume":"21","author":"Kim","year":"2013","journal-title":"Mol Ther."},{"key":"10.1016\/j.nano.2022.102614_bb0030","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201901176","article-title":"Double-layered M2e-NA protein nanoparticle immunization induces broad cross-protection against different influenza viruses in mice","volume":"9","author":"Wang","year":"2020","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.nano.2022.102614_bb0035","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1021\/acsabm.1c00240","article-title":"Skin vaccination with dissolvable microneedle patches incorporating influenza neuraminidase and flagellin protein nanoparticles induces broad immune protection against multiple influenza viruses","volume":"4","author":"Wang","year":"2021","journal-title":"ACS Appl. Bio. Mater."},{"key":"10.1016\/j.nano.2022.102614_bb0040","doi-asserted-by":"crossref","first-page":"E7758","DOI":"10.1073\/pnas.1805713115","article-title":"Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice","volume":"115","author":"Deng","year":"2018","journal-title":"Proc. Natl. Acad Sci USA"},{"key":"10.1016\/j.nano.2022.102614_bb0045","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1128\/JVI.02163-13","article-title":"Genomewide analysis of reassortment and evolution of human influenza A(H3N2) viruses circulating between 1968 and 2011","volume":"88","author":"Westgeest","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.nano.2022.102614_bb0050","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1073\/pnas.87.2.786","article-title":"Independent and disparate evolution in nature of influenza a virus hemagglutinin and neuraminidase glycoproteins","volume":"87","author":"Kilbourne","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.nano.2022.102614_bb0055","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.antiviral.2013.09.018","article-title":"Universal anti-neuraminidase antibody inhibiting all influenza a subtypes","volume":"100","author":"Doyle","year":"2013","journal-title":"Antiviral Res.<span\/>"},{"key":"10.1016\/j.nano.2022.102614_bb0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.virol.2020.08.003","article-title":"Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope","volume":"550","author":"Kim","year":"2020","journal-title":"Virology"},{"key":"10.1016\/j.nano.2022.102614_bb0065","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3390\/vaccines9070698","article-title":"Conserved influenza hemagglutinin, neuraminidase and matrix peptides adjuvanted with ALFQ induce broadly neutralizing antibodies","volume":"9","author":"Sei","year":"2021","journal-title":"Vaccines."},{"key":"10.1016\/j.nano.2022.102614_bb0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3390\/vaccines9030257","article-title":"Strategies targeting hemagglutinin as a universal influenza vaccine","volume":"9","author":"Bullard","year":"2021","journal-title":"Vaccines."},{"key":"10.1016\/j.nano.2022.102614_bb0075","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.2174\/1568026617666170224122508","article-title":"Influenza a virus nucleoprotein: a highly conserved multi-functional viral protein as a hot antiviral drug target","volume":"17","author":"Hu","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.nano.2022.102614_bb0080","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1128\/JVI.76.9.4212-4221.2002","article-title":"Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus","volume":"76","author":"Deliyannis","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.nano.2022.102614_bb0085","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/nmat3775","article-title":"Engineering synthetic vaccines using cues from natural immunity","volume":"12","author":"Irvine","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.nano.2022.102614_bb0090","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.csbj.2015.11.001","article-title":"Self-assembling protein nanoparticles in the design of vaccines","volume":"14","author":"Lopez-Sagaseta","year":"2016","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.nano.2022.102614_bb0095","doi-asserted-by":"crossref","first-page":"6331","DOI":"10.1021\/acsami.1c19192","article-title":"Polycationic HA\/CpG nanoparticles induce cross-protective influenza immunity in mice","volume":"14","author":"Dong","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.nano.2022.102614_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202300","article-title":"H7 hemagglutinin nanoparticles retain immunogenicity after >3 months of 25 degrees C storage","volume":"13","author":"Chang","year":"2018","journal-title":"PloS one."},{"key":"10.1016\/j.nano.2022.102614_bb0105","doi-asserted-by":"crossref","first-page":"2100122","DOI":"10.1002\/anbr.202100122","article-title":"Engineered nanoparticulate vaccines to combat recurring and pandemic influenza threats","volume":"2","author":"Dong","year":"2022","journal-title":"Adv. NanoBiomed Res."},{"key":"10.1016\/j.nano.2022.102614_bb0110","article-title":"Influenza NP core and HA or M2e shell double-layered protein nanoparticles induce broad protection against divergent influenza a viruses","volume":"40","author":"Ma","year":"2022","journal-title":"Nanomedicine"},{"key":"10.1016\/j.nano.2022.102614_bb0115","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/14760584.2018.1541408","article-title":"Universal influenza vaccines: from viruses to nanoparticles","volume":"17","author":"Wang","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.nano.2022.102614_bb0120","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fimmu.2013.00114","article-title":"Mechanisms of action of adjuvants","volume":"4","author":"Awate","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.nano.2022.102614_bb0125","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","author":"Pulendran","year":"2021","journal-title":"Nat Rev Drug Discovery."},{"key":"10.1016\/j.nano.2022.102614_bb0130","doi-asserted-by":"crossref","first-page":"8108","DOI":"10.1016\/S0021-9258(19)39044-1","article-title":"Structural characterization of monophosphoryl lipid a homologs obtained from salmonella minnesota Re595 lipopolysaccharide","volume":"265","author":"Johnson","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nano.2022.102614_bb0135","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s00018-008-8228-6","article-title":"Putting endotoxin to work for us: monophosphoryl lipid a as a safe and effective vaccine adjuvant","volume":"65","author":"Casella","year":"2008","journal-title":"Cell. Mol. Life. Sci."},{"key":"10.1016\/j.nano.2022.102614_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036812","article-title":"Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid a in mice","volume":"7","author":"Kamphuis","year":"2012","journal-title":"PloS one."},{"key":"10.1016\/j.nano.2022.102614_bb0145","first-page":"13","article-title":"Promising adjuvants and platforms for influenza vaccine development","author":"Zhu","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.nano.2022.102614_bb0150","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: a review on adjuvants in licensed vaccines","volume":"39","author":"Del Giudice","year":"2018","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.nano.2022.102614_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/biot.201700645","article-title":"Monophosphoryl lipid A-adjuvanted virosomes with ni-chelating lipids for attachment of conserved viral proteins as cross-protective influenza vaccine","volume":"13","author":"Dong","year":"2018","journal-title":"Biotechnol J."},{"key":"10.1016\/j.nano.2022.102614_bb0160","doi-asserted-by":"crossref","first-page":"10413","DOI":"10.1128\/JVI.00928-10","article-title":"TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector","volume":"84","author":"Rhee","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.nano.2022.102614_bb0165","first-page":"11","article-title":"Monophosphoryl-lipid a (MPLA) is an efficacious adjuvant for inactivated rabies vaccines","author":"Chen","year":"2019","journal-title":"Viruses-Basel."},{"key":"10.1016\/j.nano.2022.102614_bb0170","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1128\/jvi.68.6.3505-3511.1994","article-title":"Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza a virus nucleoprotein peptide do not protect mice against challenge","volume":"68","author":"Lawson","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.nano.2022.102614_bb0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","article-title":"Influenza","volume":"4","author":"Krammer","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"Suppl 4","key":"10.1016\/j.nano.2022.102614_bb0180","doi-asserted-by":"crossref","first-page":"D49","DOI":"10.1016\/j.vaccine.2008.07.039","article-title":"The biology of influenza viruses","volume":"26","author":"Bouvier","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2022.102614_bb0185","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1021\/acsinfecdis.8b00206","article-title":"A perspective on nanoparticle universal influenza vaccines","volume":"4","author":"Deng","year":"2018","journal-title":"ACS Infect Dis."},{"key":"10.1016\/j.nano.2022.102614_bb0190","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0378-5173(99)00370-1","article-title":"Desolvation process and surface characterisation of protein nanoparticles","volume":"194","author":"Weber","year":"2000","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.nano.2022.102614_bb0195","first-page":"9285854","article-title":"Protein based nanostructures for drug delivery","volume":"2018","author":"Verma","year":"2018","journal-title":"J. Pharm."},{"key":"10.1016\/j.nano.2022.102614_bb0200","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/02652048.2011.635218","article-title":"Albumin nanoparticles with predictable size by desolvation procedure","volume":"29","author":"Storp","year":"2012","journal-title":"J. Microencapsul"},{"key":"10.1016\/j.nano.2022.102614_bb0205","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.virol.2017.06.001","article-title":"Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza a virus challenge","volume":"509","author":"Deng","year":"2017","journal-title":"Virology"},{"key":"10.1016\/j.nano.2022.102614_bb0210","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3390\/vaccines7040169","article-title":"Development of universal influenza vaccines targeting conserved viral proteins","volume":"7","author":"Jazayeri","year":"2019","journal-title":"Vaccines."},{"key":"10.1016\/j.nano.2022.102614_bb0215","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/CVI.00156-06","article-title":"Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza","volume":"13","author":"Huber","year":"2006","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.nano.2022.102614_bb0220","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/362245a0","article-title":"Disruption of the murine IL-4 gene blocks Th2 cytokine responses","volume":"362","author":"Kopf","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.nano.2022.102614_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-24090-z","article-title":"Influenza virus infection expands the breadth of antibody responses through IL-4 signalling in B cells","volume":"12","author":"Miyauchi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.nano.2022.102614_bb0230","doi-asserted-by":"crossref","first-page":"6637","DOI":"10.1128\/JVI.72.8.6637-6645.1998","article-title":"Protective role of gamma interferon during the recall response to influenza virus","volume":"72","author":"Bot","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.nano.2022.102614_bb0235","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1080\/22221751.2020.1812436","article-title":"Protein transduction domain-mediated influenza NP subunit vaccine generates a potent immune response and protection against influenza virus in mice","volume":"9","author":"Yin","year":"2020","journal-title":"Emerg Microbes Infect."},{"key":"10.1016\/j.nano.2022.102614_bb0240","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/infdis\/jiab532","article-title":"Phase 1 randomized, placebo-controlled, dose-escalating study to evaluate OVX836, a nucleoprotein-based influenza vaccine: intramuscular results","volume":"226","author":"Withanage","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.nano.2022.102614_bb0245","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2024998118","article-title":"Intranasal vaccination with influenza HA\/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains","volume":"118","author":"Dong","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.nano.2022.102614_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2017.06.017","article-title":"A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines","volume":"261","author":"Zhu","year":"2017","journal-title":"J. Control. Release."}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963422001009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963422001009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:17:10Z","timestamp":1761549430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963422001009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":50,"alternative-id":["S1549963422001009"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2022.102614","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monophosphoryl lipid A-adjuvanted nucleoprotein-neuraminidase nanoparticles improve immune protection against divergent influenza viruses","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2022.102614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102614"}}